Pharmena S.A. Stock

Equities

PHR

PLPHRMN00011

Personal Products

Market Closed - Warsaw S.E. 11:55:44 2024-04-26 am EDT 5-day change 1st Jan Change
6.5 PLN -4.13% Intraday chart for Pharmena S.A. -2.99% -8.45%
Sales 2022 19.02M 4.71M Sales 2023 299K 74.11K Capitalization 79.08M 19.6M
Net income 2022 -1M -248K Net income 2023 28M 6.94M EV / Sales 2022 3.73 x
Net Debt 2022 8.55M 2.12M Net cash position 2023 22.05M 5.47M EV / Sales 2023 191 x
P/E ratio 2022
-39.7 x
P/E ratio 2023
2.73 x
Employees 15
Yield 2022 *
-
Yield 2023
12%
Free-Float 29.7%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.13%
1 week-2.99%
Current month-22.06%
1 month-18.55%
3 months-10.71%
6 months+5.52%
Current year-8.45%
More quotes
1 week
6.24
Extreme 6.24
6.84
1 month
6.24
Extreme 6.24
9.18
Current year
6.24
Extreme 6.24
9.18
1 year
5.30
Extreme 5.3
9.18
3 years
4.94
Extreme 4.94
17.00
5 years
4.06
Extreme 4.06
24.00
10 years
4.06
Extreme 4.06
33.48
More quotes
Managers TitleAgeSince
Chief Executive Officer - 02-11-11
Chief Tech/Sci/R&D Officer - 02-11-11
Members of the board TitleAgeSince
Director/Board Member 60 -
Director/Board Member 61 -
Director/Board Member 56 -
More insiders
Date Price Change Volume
24-04-26 6.5 -4.13% 12 070
24-04-25 6.78 -0.88% 5,726
24-04-24 6.84 +1.18% 8,962
24-04-23 6.76 +0.30% 19,211
24-04-22 6.74 -0.59% 5,335

Delayed Quote Warsaw S.E., April 26, 2024 at 11:55 am EDT

More quotes
Pharmena SA is a Poland-based producer of cosmetics and pharmaceuticals. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.
More about the company